The transition from pediatric to adult medical care represents one of the most precarious phases in the longitudinal management of patients with chronic endocrine disorders, particularly those surviving pediatric pituitary tumors (PPTs). During the ENDO 2026 conference held in June, Kevin C. J. Yuen, MD, FRCP, FEAA, a leading neuroendocrinologist and medical director of the Barrow Neurological Institute, addressed this critical care gap. In his Meet-the-Professor session, titled “Pituitary Tumor Survivorship: Transitioning from Pediatric to Adult Endocrine Care,” Dr. Yuen detailed the multifaceted challenges that arise when young patients outgrow the pediatric clinical environment and must navigate an adult healthcare system that is often ill-equipped to manage the complexities of childhood-onset pituitary disease.
The core of the issue lies in what Dr. Yuen characterizes as a "vulnerable window"—a period spanning late adolescence and early adulthood where medical, psychosocial, and developmental changes converge. For survivors of PPTs, such as craniopharyngiomas or rare pituitary adenomas, this period is marked by the attainment of peak bone mass and the final stages of pubertal development, making uninterrupted endocrine management essential. However, the lack of a standardized, coordinated pathway between pediatric and adult services frequently results in patients being "lost to follow-up," only to reappear years later with preventable complications ranging from severe hormone deficiencies to metabolic syndrome and cardiovascular disease.
The Biological and Clinical Distinctness of Pediatric Pituitary Tumors
A fundamental challenge in transitioning these patients is the inherent difference between pediatric and adult pituitary pathology. Clinical data suggests that pediatric pituitary tumors are not merely early-onset versions of adult tumors; they are often more aggressive, larger at the time of diagnosis, and more likely to be associated with genetic predispositions. While pituitary adenomas are relatively common in adults, they are rare in children, accounting for approximately 2% to 6% of all primary brain tumors in the pediatric population.
In children, the presence of a pituitary tumor frequently disrupts the delicate hormonal signaling required for linear growth and the onset of puberty. Furthermore, PPTs are more frequently associated with genetic syndromes such as Multiple Endocrine Neoplasia type 1 (MEN1), Carney Complex, and DICER1 syndrome. These genetic links necessitate a level of surveillance and familial screening that is often beyond the scope of general adult endocrinology.
The treatment of these tumors—typically involving transsphenoidal surgery, radiation therapy, or complex medical management—often leaves patients with permanent hypopituitarism. This condition requires lifelong replacement of growth hormone, thyroid hormone, adrenal steroids, and sex steroids. In the pediatric setting, these replacements are managed by specialists focused on growth and development. In the adult setting, the focus shifts to metabolic stability, bone health, and fertility, requiring a shift in clinical perspective that many patients find jarring.
Chronology of the Transition Process: From Preparation to Integration
Dr. Yuen emphasized that a successful transition is a multi-year process rather than a single event. Drawing on international models, he highlighted the importance of a structured timeline that begins long before the patient reaches the age of legal adulthood.
The "Ready Steady Go" program, a framework utilized by the National Health Service (NHS) in the United Kingdom, offers a chronological roadmap for this journey. Under this model, the transition process is initiated as early as age 11 or 12.
- The "Ready" Phase (Ages 11–14): The focus is on awareness. Clinicians begin "planting the seed" that endocrine care will be a lifelong requirement. Patients start to learn the names of their medications and the reasons for their treatments.
- The "Steady" Phase (Ages 15–17): This stage emphasizes self-management. Patients are encouraged to take a more active role in their consultations, often spending a portion of the appointment without their parents present. They learn how to refill prescriptions and recognize symptoms of adrenal crisis or other emergencies.
- The "Go" Phase (Ages 18+): The actual transfer of care occurs. This involves a formal handoff between the pediatric and adult endocrinologists, ideally through a joint clinic or a comprehensive "warm handoff" summary.
- The "Hello" Phase: The patient is successfully established within an adult clinic, having developed the autonomy to manage their own health insurance, appointment scheduling, and treatment adherence.
In the United States, the "6 Core Elements of Health Care Transition" (Got Transition 2.0) provides a similar evidence-based framework. These elements include transition policy, tracking and monitoring, readiness assessment, planning, transfer of care, and transfer completion. Despite the availability of these frameworks, Dr. Yuen noted that implementation remains inconsistent due to the fragmented nature of the American healthcare system.
Supporting Data: The Impact of Treatment Interruptions
The consequences of a failed transition are not merely theoretical; they are reflected in stark clinical data. Dr. Yuen cited a European audit revealing that approximately 70% of patients with childhood-onset growth hormone deficiency experienced a treatment interruption of more than two years during the transition to adult care.
This gap in treatment is particularly damaging because growth hormone (GH) serves critical functions beyond linear growth. In adults, GH is vital for maintaining lean body mass, reducing visceral fat, supporting bone mineral density, and ensuring cardiovascular health. When GH therapy is discontinued prematurely during the transition period, young adults are at an increased risk for early-onset osteoporosis and metabolic dysfunction.
Furthermore, survivors of craniopharyngiomas often suffer from hypothalamic obesity, a complex condition resulting from damage to the hunger and satiety centers of the brain during tumor growth or surgery. Data indicates that if weight gain is not aggressively managed during the transition years, it becomes increasingly refractory to treatment in adulthood. Early intervention during the "vulnerable window" is the only effective way to establish the lifestyle and pharmacological habits necessary to mitigate long-term morbidity.
Systemic Barriers and Institutional Challenges
The transition from pediatric to adult care is further complicated by systemic factors, including insurance coverage and geographical disparities. Pediatric hospitals are often centralized "centers of excellence" with multidisciplinary teams, whereas adult care is frequently decentralized. A patient who was treated by a team of pediatric neurosurgeons, endocrinologists, and ophthalmologists may find that their adult insurance only covers a general endocrinologist located hours away from their home.
Dr. Yuen highlighted the "insurance cliff" that many young adults face when they transition off their parents’ insurance or lose Medicaid eligibility upon reaching adulthood. This financial instability often leads to the prioritization of immediate needs over the long-term management of a "silent" condition like pituitary insufficiency.
Moreover, there is a significant shortage of adult neuroendocrinologists. Most adult endocrinologists focus primarily on diabetes and thyroid disorders, and many may feel uncomfortable managing the rare and complex sequelae of pediatric-onset pituitary tumors. This expertise gap makes it difficult for pediatricians to find suitable adult colleagues to whom they can confidently transfer their patients.
Official Guidelines and the Role of Patient Empowerment
To address these gaps, international medical societies have begun issuing joint guidance. Dr. Yuen pointed to the clinical practice guidance published in the European Journal of Endocrinology in February 2024, developed jointly by the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE).
These guidelines emphasize that transition is a "purposeful, planned process" rather than a simple administrative transfer. A key pillar of this guidance is patient empowerment. The goal is to shift the "ownership" of the disease from the parent to the patient. This involves educating the patient on the long-term implications of their condition, including fertility options, cardiovascular risk, and the importance of lifelong surveillance for tumor recurrence.
The guidance also advocates for a multidisciplinary approach in the adult setting, mirroring the care patients received as children. This includes access to reproductive endocrinologists for fertility planning, bone specialists for the management of osteopenia, and psychologists to address the neurocognitive and psychiatric comorbidities that often accompany pituitary survivors.
Analysis of Implications: A Call for Integrated Care
The insights shared by Dr. Yuen at ENDO 2026 underscore a broader need for structural reform in how the medical community handles survivorship. As medical advancements improve the survival rates of children with pituitary tumors, the population of adult survivors continues to grow.
The primary implication for clinical practice is the necessity of early intervention. Waiting until a patient is 18 to discuss the transition is often too late. By integrating transition planning into standard pediatric care from the age of 11, clinicians can mitigate the anxiety and confusion that often lead to care drop-outs.
Furthermore, healthcare institutions must recognize the financial and social value of "transition coordinators"—specialized staff members whose sole role is to bridge the gap between pediatric and adult departments. While such roles require initial investment, the long-term savings in preventing emergency room visits and managing the complications of untreated endocrine disorders are substantial.
Ultimately, the success of a transition is measured by the patient’s ability to lead a healthy, autonomous life. As Dr. Yuen concluded, while no "one-size-fits-all" solution exists for the complexities of the US healthcare system, the application of universal principles—early discussion, multidisciplinary collaboration, and patient empowerment—can significantly improve the trajectory for survivors of pediatric pituitary tumors. The growing awareness fostered by sessions at ENDO 2026 is a vital step toward ensuring that these vulnerable patients do not fall through the cracks of a fragmented system.
